

## NCLT Extremely Vulnerable Staff – March 2021 Return

This risk assessment looks at the measures taken to ensure that risks are minimised for **individuals classed as clinically extremely vulnerable**. These individuals suffer from specific medical conditions that based on knowledge of the virus so far, place someone at greatest risk of severe illness from COVID-19. Individuals with the following conditions are classed as clinically extremely vulnerable;

1. Solid Organ Transplant recipients
2. People with specific cancers:
  - People with cancer who are undergoing active chemotherapy
  - People with lung cancer who are undergoing radical radiotherapy
  - People with cancers of the blood or bone marrow such as leukaemia, lymphoma or myeloma who are at any stage of treatment
  - People having immunotherapy or other continuing antibody treatments for cancer
  - People having other targeted cancer treatments which can affect the immune system, such as protein kinase inhibitors or PARP inhibitors
  - People who have had bone marrow or stem cell transplants in the last 6 months, or who are still taking immunosuppression drugs
3. People with severe respiratory conditions including all cystic fibrosis, severe asthma and severe chronic obstructive pulmonary disease (COPD)
4. People with rare diseases that significantly increase the risk of infections (such as SCID, homozygous sickle cell)
5. People on immunosuppression therapies sufficient to significantly increase the risk of infection
6. People with problems with their spleen, for example splenectomy
7. Adults with Down's syndrome
8. Adults on dialysis or with chronic kidney disease (stage 5)
9. **Pregnant individuals** with significant heart disease, congenital or acquired
10. Other people who have also been classed as clinically extremely vulnerable, based on clinical judgement and an assessment for their needs by a GP or hospital clinician

People who fall in this group should have been contacted by their doctor to tell them they are clinically extremely vulnerable and will have received a shielding letter.

Area of Concern	Risk	Risk Level Before Controls <i>Low = 1-2</i> <i>Medium = 3-4</i> <i>High = 6+</i>	Control Measures	Residual Risk Level <i>Low = 1-2</i> <i>Medium = 3-4</i> <i>High = 6+</i>	Additional Actions/Resources Required	Links to Relevant Policies or Government Advice	Responsibility	Control Measures in Place
Communication	<b>Difficulties identifying individuals with the listed medical conditions</b>	6	Confirm with staff members that they belong to the Clinically Extremely Vulnerable Group.  Request sent out via email to all staff members to update NCLT if their medical status has changed.	1			HR Manager	
<b>Safety attending site</b>	<b>Risk of contact with individual infected with</b>	<b>6</b>	<b>All CEV individuals will continue to work from home while shielding</b>	<b>1</b>	<b>Monitor government advice on shielding and pass on details of</b>			

	COVID-19		advice provided by the government is in place.		changes to staff members.			
--	----------	--	--	--	---------------------------	--	--	--

Signed (Health and Safety Manager)

Date 1/3/21